IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
PR Newswire•27/10/2026•08:33 ET
0
Key Highlights
- ➤IceCure (ICCM) completed the first ChoICE Study treatment at West Cancer Center.
- ➤ChoICE Study plans approximately 400 patients across up to 30 U.S. sites.
- ➤Participating sites may also commercially offer ProSense® to eligible non-study patients.
- ➤FDA-cleared indication covers low-risk breast tumors ≤1.5 cm in patients aged 70 and older.
Expert Statements
Richard E. Fine, MD, FACS; board-certified breast oncology surgeon and Director of the Breast Surgical Oncology Fellowship Program at West Cancer Center & Research Institute
“Treating the first patient marks an exciting milestone for the ChoICE Study, which we expect to generate additional clinical data supporting cryoablation and help pave the way for its broader clinical adoption among appropriately selected breast cancer patients.”
Eyal Shamir, Chief Executive Officer of IceCure Medical
“We believe initiating treatment in the ChoICE Study is a key step in executing our U.S. post-market strategy for ProSense®. West Cancer Center is an ideal partner to lead this effort, and as we expand our network of study sites, we expect each one to strengthen our commercial footprint and broaden access to ProSense® for eligible patients.”
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation PR Newswire
First patient enrolled and treated at West Cancer Center in Tennessee, USA
Get started
Create a free account to read the full story.